Literature DB >> 1768565

Exercise performance during captopril and atenolol treatment in hypertensive patients.

M A Van Baak1, F M Koene, F T Verstappen, E S Tan.   

Abstract

1. Maximal aerobic exercise capacity, submaximal endurance exercise performance, and exercise haemodynamics have been studied in sixteen patients with mild to moderate essential hypertension during treatment with captopril and atenolol. 2. Administration of atenolol (1 x 100 mg day-1) or captopril (1 x 100 mg day-1) for 6 weeks resulted in similar supine and erect systolic and diastolic blood pressures. Heart rate was significantly lower during atenolol treatment. 3. Exercise heart rate and systolic blood pressure were significantly lower during atenolol than during captopril treatment, exercise diastolic blood pressure (at 100W) did not differ significantly. With atenolol exercise cardiac output was significantly lower and exercise stroke volume significantly higher than with captopril. 4. Maximal work rate, maximal oxygen consumption and maximal heart rate were significantly lower during atenolol than during captopril treatment (respectively 6%, 8% and 25%). Maximal respiratory exchange ratio and lactate concentration did not differ. 5. No statistically significant difference in submaximal endurance time between atenolol and captopril was found. Endurance time was reduced by 19% during atenolol and by 13% during captopril as compared with placebo. No difference in rating of perceived exertion between atenolol and captopril was present. 6. The results indicate that atenolol will reduce blood pressure during exercise more effectively than captopril in patients with hypertension. The limitation of submaximal endurance exercise performance by both agents is of similar magnitude. This may be regarded as an unwanted side effect in certain physically active patients with hypertension.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1768565      PMCID: PMC1368553     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  Determination of mixed venous CO2 tensions by rebreathing.

Authors:  C R COLLIER
Journal:  J Appl Physiol       Date:  1956-07       Impact factor: 3.531

2.  Twenty-four hour effects of oxprenolol Oros and atenolol on heart rate, blood pressure, exercise tolerance and perceived exertion.

Authors:  M A van Baak; F T Verstappen; B Oosterhuis
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  The two-period cross-over clinical trial.

Authors:  M Hills; P Armitage
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335

Review 4.  Beta-adrenoceptor blockade and exercise. An update.

Authors:  M A Van Baak
Journal:  Sports Med       Date:  1988-04       Impact factor: 11.136

5.  Exercise haemodynamics and maximal exercise capacity during beta-adrenoceptor blockade in normotensive and hypertensive subjects.

Authors:  M A van Baak; F M Koene; F T Verstappen
Journal:  Br J Clin Pharmacol       Date:  1988-02       Impact factor: 4.335

6.  Evidence for a participation of the kallikrein-kinin system in the regulation of muscle metabolism during muscular work.

Authors:  G Dietze; M Wicklmayr
Journal:  FEBS Lett       Date:  1977-03-01       Impact factor: 4.124

7.  Acute and chronic systemic and pulmonary hemodynamic effects of angiotensin converting enzyme inhibition with captopril in hypertensive patients.

Authors:  R Fagard; A Amery; T Reybrouck; P Lijnen; L Billiet
Journal:  Am J Cardiol       Date:  1980-08       Impact factor: 2.778

8.  Hemodynamic response to converting enzyme inhibition at rest and exercise in humans.

Authors:  R Fagard; P Lijnen; L Vanhees; A Amery
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1982-09

9.  The estimation of carbon dioxide pressure of mixed venous blood during exercise.

Authors:  N L Jones; E J Campbell; G J McHardy; B E Higgs; M Clode
Journal:  Clin Sci       Date:  1967-04       Impact factor: 6.124

10.  The effects of antihypertensive therapy on the quality of life.

Authors:  S H Croog; S Levine; M A Testa; B Brown; C J Bulpitt; C D Jenkins; G L Klerman; G H Williams
Journal:  N Engl J Med       Date:  1986-06-26       Impact factor: 91.245

View more
  2 in total

1.  Exercise tolerance with nebivolol and atenolol.

Authors:  L M Van Bortel; M A van Baak
Journal:  Cardiovasc Drugs Ther       Date:  1992-06       Impact factor: 3.727

2.  The pharmacokinetic and pharmacodynamic interactions of ramipril with propranolol.

Authors:  J M van Griensven; M Seibert-Grafe; H C Schoemaker; M Frölich; A F Cohen
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.